On July 31, Eastern Time, Novo Nordisk (NVO) fell more than 10% at one point, marking its largest single-day decline since February 23, 2026. As of press time, the stock remained down 8.84% at $47.05. Novo Nordisk announced on Friday that its high-profile investigational heart drug, ziltivekimab, failed to meet the primary endpoint in a large-scale late-stage clinical trial.

TradingKeyFri, Jul 31

Novo Nordisk Sues Eli Lilly for False Advertising: Weight-Loss Drug Data War Escalates, GLP-1 $100 Billion Market Fight Heats Up

TradingKey - Novo Nordisk (NVO) has officially filed a lawsuit in the U.S. District Court for the District of New Jersey, alleging that Eli Lilly’s (LLY) advertisements for its blockbuster weight-loss drug Zepbound and diabetes injection Mounjaro are misleading and violate federal and state laws concerning false advertising and unfair competition. The essence of the lawsuit is a data war between the two pharmaceutical giants over the multi-hundred-billion-dollar GLP-1 drug market, where the key weapon on the battlefield is a set of clinical comparison data alleged to be "outdated."

TradingKeyTue, Jul 21

Eli Lilly Zepbound Returns to CVS Formulary, Pre-Market Shares Rise as Much as 2%

TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.

TradingKeyThu, May 28

Eli Lilly Weight-Loss Drug Retatrutide Posts Impressive Data; Can Novo Nordisk Break Through After Falling Behind Again?

TradingKey - On May 21, Eastern Time, Eli Lilly announced the results of the pivotal Phase 3 clinical trial (TRIUMPH-1) for its next-generation weight-loss drug, Retatrutide. As the world's first "triple agonist" targeting GIP, GLP-1, and glucagon receptors, its efficacy data has comprehensively sur

TradingKeyMon, May 25

Hold or Diversify? Why This Forgotten Industry Deserves a Look

Recent market performance has been more than just strong

TradingKeyThu, May 14

Is Novo Nordisk Positioned for Recovery in 2026 Amid Rising Competition and AI Innovations?

TradingKey - Since 1923, Novo Nordisk (NVO) has thrived as a pharmaceutical company based in Denmark, primarily focusing on two business areas: Obesity and diabetes, and Rare Diseases.

TradingKeyMon, May 4

Cross-Sector Collaboration Between Pharma and AI. Novo Nordisk Joins Forces With OpenAI, Can It Regain Market Dominance in the Competition With Eli Lilly?

TradingKey - Danish pharmaceutical manufacturer Novo Nordisk (NOVO) stated on Tuesday that it will partner with OpenAI to deploy artificial intelligence across all aspects of its business, from drug discovery to manufacturing and commercial operations.

TradingKeyWed, Apr 15

Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market

TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.

TradingKeyThu, Mar 12

Novo Nordisk Shares Plunge, Eli Lilly Zepbound Multi-Dose Approved, Weight-Loss Drug Throne Changing Hands?

TradingKey - Amid the ongoing surge in the global weight-loss drug market, Eli Lilly (LLY) announced that its Zepbound four-dose KwikPen device has received U.S. FDA approval. Following the announcement, the company's share price rose 4.86% in a single day, further strengthening market expectations

TradingKeyTue, Feb 24

What to Expect From Eli Lilly in 2026? Is LLY Stock a Good Buy Now?

The company’s main goal and focus in 2026 will be to maintain its leadership position in weight management, whilst expanding further into additional therapeutic areas, so that revenue growth will not be dependent on a singular product. It is expected that Eli Lilly’s stocks will serve as a predictor

TradingKeyWed, Feb 4